Farmas USA

BBP offers a different approach to biotech investing by handpicking only firms that have attained FDA approval for their leading drug. The fund is offered by BioShares alongside launched a sister fund, BBC, which targets biotech firms in the clinical trial stage. BBP is likely to tilt smaller than our neutral cap-weighted benchmark because the fund equal-weights its holdings, and it dips into micro-caps as well. Unsurprisingly, risk is elevated compared to our benchmark. BBP can be tricky to trade at any scale. Onscreen volume is thin and spreads are large, while the small-cap basket may cause some liquidity problems for larger investors. It also charges a very high expense ratio for this segment. Overall, BBP provides an alternative but pricey take on the biotech segment.

http://www.etf.com/BBP

BBP/Semanal 

BBC / semanal

Uy que futuros mas ricos +0.6% :)))

EXEL

Resultados fase 3 (ampliación de uso de un medicamento ya aprobado): a mi no me parecen gran cosa (mejoras menores), y parece que al PM tampoco (anda en +1%)...

Results from late-stage study of Exelixis' Cabometyx in liver cancer published in NEJM

https://seekingalpha.com/news/3367996-results-late-stage-study-exelixis-cabometyx-liver-cancer-published-nejm

Exelixis announces that results from the Phase 3 CELESTIAL clinical trial evaluating CABOMETYX (cabozantinib) in treatment-experienced patients with hepatocellular carcinoma (HCC) have been published in the New England Journal of Medicine (NEJM).

Median overall survival (OS) in the treatment group was 10.2 months compared to 8.0 months for placebo. Median progression-free survival (PFS) was 5.2 months versus 1.9 months for control. Objective response rate (ORR) was 4.0% compared to 0.4% for placebo.

In a subgroup of patients who previously received only Bayer's NEXAVAR (sorafenib) (70% of subjects), median OS was 11.3 months vs. 7.2 months for placebo, Median PFS was 5.5 months compared to 1.9 months for control.

The company's U.S. marketing application seeking approval for the indication is currently under FDA review with an action date of January 14, 2019.

Pero esos resultados ya los sacaron en enero de este año, la noticia aquí es que los publican en NEJM y poco más, el prestigio que eso da, etc.

EXEL

Entendido... ya me descuadraba tan poca reacción.

EXEL

Esto es nuevo... Ahora mi broker( DeGiro ), dice que para determinados valores, no se puede poner más de una órden de compra/venta. Es decir, para NVAX, no puedo poder una órden de compra y otra de venta, tengo que elegir entre poner una u otra. De momento, me ha pasado solo con este valor. A alguien más le pasa?

ACAD 1h

vamossss!!!!!!